New application of flos magnoliae volatile oil, pharmaceutical composition for treating chronic prostatitis as well as preparation method and quality detection method of pharmaceutical composition

Through the combination of magnolia and lavender volatile oil, it is prepared into a cream preparation, which acts directly on the prostate, solving the problem that existing drugs are difficult to penetrate the prostate barrier, achieving better therapeutic effects and fewer side effects.

CN118903251AActive Publication Date: 2024-11-08XIANYANG VOCATIONAL TECHN COLLEGE
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411033759.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-08
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

Existing treatments for chronic prostatitis are difficult to penetrate the prostate barrier, resulting in poor efficacy and gastrointestinal side effects.

Method used

The combination of volatile oil of magnolia and volatile oil of lavender is prepared into a cream preparation, which is administered rectally or locally injected in the prostate, and uses its anti-inflammatory, anti-allergic and antioxidant effects to directly act on the prostate, bypassing the prostate barrier.

Benefits of technology

It significantly reduces the pain of chronic prostatitis, improves the treatment effect, avoids gastrointestinal side effects, provides a new route of administration, and enhances the synergistic effect of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903251A_ABST
    Figure CN118903251A_ABST
Patent Text Reader

Abstract

The invention provides application of flos magnoliae volatile oil in preparation of a medicine for treating chronic prostatitis. The invention further provides a pharmaceutical composition for treating chronic prostatitis. The pharmaceutical composition comprises flos magnoliae volatile oil and lavender volatile oil. The medicine comprises the following components in parts by weight: 1.5-2.5 parts of flos magnoliae volatile oil and 0.5-1.5 parts of The invention also provides a preparation method and application of the extract. According to the invention, the medicinal function of the magnolia flower volatile oil is further developed, and the treatment of chronic prostatitis by the magnolia flower volatile oil is subjected to related research. The lavender volatile oil and the magnolia flower volatile oil are compatible, so that the chronic prostatitis can be better treated. The lavender volatile oil and the flos magnoliae volatile oil are prepared into a cream preparation, the cream preparation is externally applied to the prostate of a rat with chronic prostatitis, the drug effect is achieved through transdermal administration, the side effects of gastrointestinal tracts and the synergistic interaction of prostate barriers and raw materials are avoided, and a new thought is provided for the administration route for treating chronic prostatitis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a new use of magnolia volatile oil, a pharmaceutical composition for treating chronic prostatitis, a preparation method and a quality detection method thereof. Background Art

[0002] Prostatitis is a disease of the male urogenital system. Among them, type III prostatitis (chronic prostatitis / chronic prostatic pain syndrome, CP / CPPS), which accounts for about 90-95% of all prostatitis, is the most common type of prostatitis. The pathogenesis of chronic prostatitis is complex. At present, chronic prostatitis has been studied in depth, but it has not yet been fully elucidated. Its pathogenic factors include infection, oxidative stress, abnormal urination function, immune response disorders, endocrine disorders, abnormal neural regulation, mental and emotional factors, etc. At present, antibiotics, α-receptor blockers, etc. are commonly used drugs in clinical practice, but these drugs are poorly absorbed orally and cannot reach nerve endings. Therefore, in order to better treat chronic prostatitis, scholars are committed to the development of natural drugs for the treatment of chronic prostatitis with less toxic side effects.

[0003] The main difficulty in the treatment of prostatitis at present is the existence of the prostate barrier. The prostate barrier usually refers to some structural and functional characteristics in the prostate tissue, which can protect the prostate from harmful substances and also affect the penetration and distribution of drugs. There are several aspects: 1. Blood-prostate barrier (BPB) This is a special barrier that limits the exchange of substances between the blood and prostate tissue, making it difficult for some drugs to penetrate into the prostate, thereby affecting the concentration and efficacy of drugs in the prostate. 2. Prostate epithelial barrier: Prostate epithelial cells form a barrier through tight junctions to control the entry and exit of substances (Cui Dong, et al., Study on the barrier function of prostate capillary endothelial cells, [J]. Journal of the Third Military Medical University, 2016, 38 (4): 385-389)); 3. Prostate matrix barrier: The matrix components of the prostate, such as connective tissue and smooth muscle, may also have a certain restrictive effect on the exchange of substances. 4. Prostate capsule: A thin layer of fibromuscular tissue wrapped around the surface of the prostate substance is called the prostate capsule, which together with the prostate sheath constitutes the outer protective layer of the prostate. 5. The anatomical structure of the prostate: The location of the prostate, its adjacent relationships, and its internal structures, such as alveoli and ducts, also affect the distribution of substances in the prostate. For natural plants, it is even less likely to pass through the prostate barrier and reach the lesion site.

[0004] Lavandula angustifolia Mill. (Labiatae) is a perennial evergreen subshrub of the genus Lavandula, which is distributed worldwide. Lavender volatile oil is an aromatic herbal extract, mainly containing linalool, linalyl acetate, lavandin acetate and camphor, and is often used in a variety of clinical conditions, such as anxiety, pain and inflammation. Lavender volatile oil has good anti-inflammatory activity. Magnoliae Flos volatile oil is a plant of the Magnoliaceae family. The active ingredients of Magnoliae Flos volatile oil are eucalyptol, farnesol, α-pinene and β-pinene, which have good anti-inflammatory, anti-allergic, antioxidant and antibacterial effects. However, there are many different structural types of components contained in volatile oil, and not all of them are active ingredients. At present, there are few studies on the effective components of volatile oil and their dose-effect relationship, so the lack of research in this area limits its application. At present, there is no literature report on the combination of lavender and magnoliae volatile oil for the treatment of prostatitis. Summary of the invention

[0005] The technical solution of the present invention is to provide a new use of magnolia volatile oil, specifically, the use in preparing a medicine for chronic prostatitis. Another technical solution of the present invention is to provide a pharmaceutical composition for treating chronic prostatitis, a preparation method and use thereof, and a quality detection method of the pharmaceutical composition.

[0006] The invention provides use of magnolia volatile oil in preparing medicine for chronic prostatitis.

[0007] Wherein, the drug is administered rectally or injected locally directly into the prostate.

[0008] The invention provides a pharmaceutical composition for treating chronic prostatitis, which comprises magnolia volatile oil and lavender volatile oil; the weight ratio is: magnolia volatile oil 1.5-2.5 parts, lavender volatile oil 0.5-1.5 parts;

[0009] The magnolia volatile oil contains 1%-60% w / w eucalyptol and 1%-30% w / w farnesol; the lavender volatile oil contains 5%-55% w / w linalool and 3%-40% w / w linalyl acetate.

[0010] The weight ratio of magnolia volatile oil and lavender volatile oil is:

[0011] 2 parts of magnolia volatile oil and 1 part of lavender volatile oil.

[0012] The pharmaceutical composition of the present invention is prepared from the raw materials as active ingredients, and pharmaceutically acceptable excipients or auxiliary ingredients are added to form a commonly used pharmaceutical preparation; the preparation is a rectal administration, direct local injection into the prostate.

[0013] The rectal administration preparations include suppositories, enemas, foams, gels and creams.

[0014] The cream is an O / W cream, wherein each 100 g contains the following raw materials and matrix by weight:

[0015] Liquid paraffin 6g, octadecyl alcohol 7.5g, white vaseline 10g, magnolia: lavender essential oil (2:1) 2g, ethyl paraben 0.1g, sodium lauryl sulfate 1g, glycerin 5g.

[0016] The present invention provides a method for preparing the pharmaceutical composition for treating chronic prostatitis, wherein the emulsion comprises the following steps:

[0017] a. Weigh the raw materials of various weight ratios; wherein the oil phase is liquid paraffin and white vaseline, and the water phase is stearyl alcohol, glycerin and water;

[0018] b. Heat the oil phase and water phase to 80°C respectively, and add volatile oil after the oil phase is completely melted;

[0019] c. Continuously stir the oil phase and the water phase to mix them well; add ethyl paraben and sodium lauryl sulfate to the water phase;

[0020] d. When the temperatures of the two phases are the same, slowly pour the water phase into the oil phase and continue stirring in the same direction; first increase the speed, then gradually slow down until emulsification is complete; after stopping heating, continue stirring to room temperature until the cream is formed.

[0021] The invention provides use of the pharmaceutical composition in preparing medicine for chronic prostatitis.

[0022] The present invention provides a method for detecting a pharmaceutical composition for treating chronic prostatitis, which adopts a GC-MS method for detection and comprises the following steps:

[0023] a. Sample pretreatment: Accurately measure 100 μL of magnolia volatile oil and 100 μL of lavender volatile oil into two different 10 mL brown volumetric flasks, dilute to volume with n-hexane, mix well, add anhydrous sodium sulfate to remove moisture, filter through a 0.22 μm filter membrane, and drop into a sample injection bottle for later use;

[0024] b. GC-MS conditions are:

[0025] The gas chromatography-mass spectrometry conditions of volatile oil of Magnolia odorifera were as follows: Agilent HP-5ms (30m×250μm×0.25μm) capillary column, carrier gas He, no splitting, injection volume 3.0μL, flow rate 1mL / min; the starting temperature was 55℃, 8℃ / min increased to 80℃, 6℃ / min increased to 160℃ (holding time 2min), 8℃ / min increased to 200℃, 3℃ / min increased to 250℃ (holding time 2min); the mass spectrometry conditions were as follows: ionization source EI ion source temperature 230℃, ionization energy 70eV, transfer line temperature 280℃, ion source temperature 230℃, quadrupole temperature 150℃, solvent delay time 3min, scanning mass scanning range 28–555amu;

[0026] Mass spectrometry conditions for lavender essential oil: Agilent HP-5ms (30m×250μm×0.25μm) capillary column, carrier gas He, no splitting, injection volume 1.0μL, flow rate 1mL / min; starting temperature 40℃ (holding time 1min), 5℃ / min to 90℃ (holding time 1min), 10℃ / min to 260℃ (holding time 6min); mass spectrometry conditions are as follows: ionization source EI ion source temperature 230℃, ionization energy 70eV, transfer line temperature 280℃, ion source temperature 230℃, quadrupole temperature 150℃, solvent delay time 5min, scanning mass scanning range 30–400amu.

[0027] According to the perspective of TCM syndrome differentiation, the main pathogenesis of chronic prostatitis is qi stagnation and blood stasis, liver and kidney yin deficiency, damp heat and blood stasis. The present invention uses the volatile oil of magnolia and lavender in combination. Magnolia tastes pungent, warm in nature, and belongs to the lung and stomach meridians; lavender tastes pungent, cool in nature, and belongs to the spleen and lung meridians; and the volatile oil has a fragrant and pungent and warm aroma, which can regulate the human body's qi. The two are used together to achieve the effects of soothing the liver and regulating qi, warming and unblocking the meridians, and dispersing blood stasis and relieving pain, which can greatly reduce the pain of chronic prostatitis. Especially when magnolia: lavender = 2:1, it has a significant synergistic effect.

[0028] The present invention further develops the medicinal function of magnolia volatile oil and conducts relevant research on its treatment of chronic prostatitis. Lavender volatile oil and magnolia volatile oil are combined to better treat chronic prostatitis. Lavender volatile oil and magnolia volatile oil are prepared into a cream preparation, which is applied externally to the prostate of rats with chronic prostatitis, and the drug effect is exerted through transdermal administration, avoiding gastrointestinal side effects and prostate barrier. The synergistic effect achieved by the raw materials provides a new idea for the administration route for treating chronic prostatitis. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 Single factor test result diagram;

[0030] Figure 2 Response surface experiment results diagram;

[0031] Figure 3 Prostate index and kit result graphs (including (A) prostate index result graph, (B) TNF-α result graph, (C) IL-1β result graph, and (D) IL-6 result graph);

[0032] Figure 4 Prostate index and kit result graphs of cream and volatile oil groups (including (A) cream prostate index result graph, (B) cream TNF-α result graph, (C) cream IL-1β result graph, (D) cream IL-6 result graph);

[0033] Figure 5 HE staining results;

[0034] Figure 6 HE staining results of magnolia lavender essential oil cream;

[0035] Figure 7 Immunohistochemistry results;

[0036] Figure 8 Immunohistochemistry results (including (A) COX2 results; (B) p-AKT results; (C) p-p65 results; (D) p-PI3K results);

[0037] Fig. 9 Immunohistochemical results of magnolia lavender essential oil cream;

[0038] Fig.10 Cream immunohistochemistry results (including (A) cream COX2 results, (B) cream p-AKT results, (C) cream p-p65 results, (D) cream p-PI3K results). DETAILED DESCRIPTION

[0039] The lavender volatile oil used in the present invention was purchased from Xinjiang Yiparhan Spice Co., Ltd.; the magnolia volatile oil was purchased from Ningbo Xiangxiang Wharf Biotechnology Co., Ltd.

[0040] Example 1 Preparation of the cream of the present invention

[0041] Liquid paraffin 6g, octadecyl alcohol 7.5g, white vaseline 10g, magnolia: lavender (2:1) volatile oil 2g, ethyl paraben 0.1g, sodium lauryl sulfate 1g, glycerin 5g, add water to 100g.

[0042] The specific preparation process is:

[0043] 1) Take liquid paraffin and white vaseline, heat to 80°C to melt, and mix well to obtain an oil phase; take octadecyl alcohol, glycerin and water, heat to 80°C, and mix well to obtain a water phase;

[0044] 2) Take the oil phase obtained in step 1), add volatile oil, and mix well. Take the water phase obtained in step 1), then add ethyl paraben and sodium lauryl sulfate, and mix well. Finally, slowly add the water phase to the oil phase, stirring while adding until cooled to room temperature, and obtain the product.

[0045] Example 2 Screening test of auxiliary materials of cream of the present invention

[0046] Cream is a semi-solid preparation that is evenly mixed by mixing and dispersing drugs in an emulsion-type matrix. Cream preparations can avoid the first-pass effect of the liver and gastrointestinal irritation, and directly act on the target site to exert a therapeutic effect. Using cream technology, magnolia and lavender volatile oils are combined to prepare a cream to solve the poor experience when using volatile oils.

[0047] 1 Pre-prescription studies

[0048] 1.1W / O type cream and O / W type cream

[0049] In order to produce a volatile oil cream with magnolia and lavender volatile oil, a series of preliminary research work was carried out. Cream is a product divided into two types: W / O type and O / W type. The W / O type has a lower greasy feeling, is very easy to apply, and brings a slow cooling effect when the water evaporates from the skin surface; the latter can be mixed with water, has a lighter greasy feeling, is easy to apply and wash, and has a faster drug release rate and skin absorption rate. Based on these characteristics, there are also some relevant literature reports showing that compared with W / O type cream, O / W type cream has stronger advantages in drug release rate, skin penetration and stability. Therefore, this experiment adopted the method of preparing O / W type cream.

[0050] 1.2 Matrix of O / W cream

[0051] When preparing O / W creams, the amount of water phase is usually greater than the oil phase, and an O / W emulsifier is required. An ideal cream matrix should be stable, uniform and fine, absorbent, non-irritating, not affect wound healing, easy to wash off, and have good drug release properties.

[0052] 1.3 Water phase

[0053] The aqueous phase often uses polyethylene glycol, cellulose derivatives and an appropriate amount of polyols, such as propylene glycol and glycerol, which can lower the freezing point of the aqueous phase.

[0054] 1.4 Oil phase

[0055] The oil phase commonly used is vaseline, liquid paraffin, solid paraffin, lanolin, etc., but the dosage must be moderate to avoid affecting the absorption of the cream.

[0056] 1.5 Emulsifier

[0057] Emulsifiers play a vital role in the preparation, stability and efficacy of creams. Creams can choose W / O or O / W emulsifiers according to their types. The selection of emulsifiers is mainly based on the HLB value. Common emulsifiers include Tween-80, Span-80 and sodium dodecyl sulfate.

[0058] 1.6 Additives

[0059] Since creams are prone to mildew during storage, preservatives and other additives need to be added. Commonly used preservatives include hydroxyphenyl esters, benzoic acid, sorbic acid and benzalkonium bromide, among which hydroxyphenyl ester preservatives are commonly used in creams, usually at a concentration of 0.1%.

[0060] 2. Screening of cream formulations

[0061] 2.1 Single-factor experimental design

[0062] Using a single-factor experiment and combined with literature reports, this experiment took A (magnolia: lavender (2:1) volatile oil), B (liquid paraffin), C (octadecyl alcohol), D (white vaseline), E (propylene glycol), and F (sodium lauryl sulfate) as investigation factors, and each factor took 5 levels. The single-factor experimental level design is shown in Table 1.

[0063] Table 1 Single factor experimental design

[0064]

[0065]

[0066] 2.2 Evaluation indicators and scoring criteria

[0067] This experiment used a comprehensive scoring method as an indicator to screen prescriptions, with a total score of 100 points. The appearance (30 points), physical stability (30 points), droplet size (20 points), and moisturizing properties (20 points) of the cream were examined separately.

[0068] Table 2 Quality evaluation indicators and scoring standards for creams

[0069]

[0070] 2.2.1 Inspection of appearance characteristics

[0071] The appearance evaluation mainly evaluates the five indicators of the cream: gloss, uniformity, fineness, viscosity and coating. The score range of each indicator is 0-6 points, and the score is scored on a 1-point scale. Finally, the sum of the scores of each indicator is calculated to be the appearance score of the cream.

[0072] The specific evaluation process is as follows: First, 6 evaluators observe with the naked eye whether each prescription of the cream is shiny, score it, and then find the average value. Then, similarly, 6 evaluators observe with the naked eye whether the color of each prescription of the cream is consistent, score the uniformity, and then find the average value. Once again, 6 evaluators observe with the naked eye whether the cream is delicate and free of coarse particles, score it, and then find the average value. After that, 6 evaluators take an appropriate amount of cream and apply it on the back of the hand, feel whether it is greasy, score it, and then find the average value. Finally, 6 evaluators take an appropriate amount of cream and apply it on the back of the hand, feel whether it can be quickly spread, and score it, and finally find the average value as the coating score result.

[0073] Table 3 Evaluation indexes and scoring criteria for the appearance properties of creams

[0074]

[0075] 2.2.2 Physical stability investigation

[0076] The physical stability test of the cream is divided into centrifugation, heat resistance and low temperature resistance tests. Each index is scored from 0 to 10 points, and the total score of the three indicators is the physical stability score.

[0077] The specific evaluation process is as follows: Centrifugation experiment, take 1mL of each prescription sample and place it in a 1.5mL centrifuge tube, centrifuge at 3000rpm for 30min, observe the properties of the cream in each group of centrifuge tubes, and judge whether oil-water stratification occurs. Score according to 1 point 1 level, if no stratification occurs, the full score is 10 points. Heat resistance experiment, take 15 grams of samples from each position, put them in a 25ml beaker, seal them with plastic wrap, and then put them in a constant temperature oven, keep the temperature at 55±2℃ for 6 hours. After that, take out the sample and wait for it to cool to room temperature to observe whether it becomes hard, thin, rough, bubbling, oil-water separation, etc. Each indicator is scored according to the degree of change, and 2 points are given if there is no change. Use 1 point 1 level downgrade scoring. For the low temperature resistance experiment, 15g of each prescription sample was placed in a sealed bag, first pre-frozen at 4℃ for 2 hours, then quickly placed at -20℃, taken out after 24 hours, and observed to see if there was cracking, hardening, thinning, roughening, or oil-water stratification after it was placed at room temperature. Each indicator was scored with 2 points, and the score was given step by step according to the degree of change: 2 points for no change, 0 points for a large change, and the score was downgraded by 1 point.

[0078] Table 4 Physical stability evaluation indexes and scoring criteria for ointments

[0079]

[0080] 2.2.3 Investigation of droplet size and uniformity

[0081] Apply an appropriate amount of cream evenly on a glass slide, then cover it with a cover glass and observe the size and distribution of the droplets under a 100x microscope. Based on the observation results, the scoring criteria are divided into three levels: good, medium, and poor, with 8-10 points for good, 4-7 points for medium, and 0-3 points for poor. By evaluating the size and uniformity of the droplets, it is concluded that the cream with a high score has the characteristics of small particle size and uniform particle size distribution.

[0082] Table 5 Evaluation indexes and scoring criteria for cream droplet size and uniformity

[0083]

[0084] 2.2.4 Moisture retention study

[0085] 2 g of the cream was applied on a glass slide, accurately weighed, and placed in a 37°C incubator for 8 hours. Then, it was taken out and accurately weighed in triplicate to calculate the average water loss rate of the cream.

[0086] Moisture retention scoring method: score = 20 - water loss rate × 20. The lower the score, the better the moisturizing property of the cream.

[0087] 2.3 Analysis of single factor experimental results

[0088] Depend on Figure 1 It can be seen that the quality of the magnolia: lavender (2:1) volatile oil cream is affected by the dosage of magnolia: lavender (2:1) volatile oil, liquid paraffin, octadecanol, white vaseline, glycerin and sodium lauryl sulfate. Except for the trend of gradually decreasing dosage of magnolia: lavender (2:1) volatile oil, the dosage of other ingredients basically shows a relationship of first increasing and then decreasing. According to the results of the single factor experiment, the best prescription ratio is magnolia: lavender (2:1) volatile oil 2%, liquid paraffin 6%, octadecanol 7.5%, white vaseline 10%, glycerin 5%, sodium lauryl sulfate 1%, and the cream has the highest score. According to the size of the influence relationship of each factor, sodium lauryl sulfate, octadecanol and glycerin are selected for response surface experimental design.

[0089] Table 6 Scores of single factor experiment

[0090]

[0091]

[0092] 2.4 Response surface experimental design

[0093] The optimal level of each single factor was determined by the single factor experimental results, and the Box-Behnken Design experiment was designed using Design-Expert8.0.6 software. Sodium lauryl sulfate, octadecyl alcohol and glycerol were selected for response surface experiments. The response surface experimental factors and levels are shown in the table below. All experiments were conducted three times.

[0094] Table 7 Factors and levels of response surface experiment

[0095]

[0096] 2.5 Response surface optimization test results

[0097] 2.5.1 Response surface test results

[0098] Design-Expert 8.0.6 software was used for response surface experimental design, see the table below.

[0099] Table 8 Response surface design results

[0100]

[0101] 2.5.2 Establishment of regression model and significance analysis

[0102] According to the results in the above table, polynomial fitting was performed on the dosage of sodium lauryl sulfate (A), octadecyl alcohol (B) and glycerol (C) to establish a multivariate quadratic regression equation:

[0103] Quality score of magnolia and lavender combined with essential oil cream

[0104] =95.20+0.81×A+0.25×B-0.31×C-0.025×AC-3.79×A 2 -3.56×B 2 -3.09×C 2

[0105] Use software to perform variance analysis of the response surface regression model and obtain the variance analysis table, as shown in the following table:

[0106] Table 9 Analysis of variance of regression model

[0107]

[0108]

[0109] From the above table, we can see that the p-value of the model is <0.0001, and the p of Lack of Fit is 0.9997>0.05, indicating that the regression model is statistically significant and can describe the relationship between the three factors and the quality score of the cream. 2 =0.9939, adjusted R 2 =0.9860, which also proves the validity of the model. Therefore, the regression equation can be used to predict the changes of the scores of the cream with the three factors.

[0110] Through the interactive analysis of the dosage of sodium lauryl sulfate, stearyl alcohol and glycerol, it was found that these three factors have different effects on the quality of the cream. According to the F value, it can be concluded that the most influential factor is sodium lauryl sulfate, followed by glycerol, and finally stearyl alcohol. The response surface test results are shown in the figure Figure 2 .

[0111] 3 Conclusion

[0112] This study screened the prescription of the magnolia lavender volatile oil cream and selected the best dosage of ingredients. Then, three factors that greatly affected the quality were determined through single factor experiments and response surface experiments, and the preparation process of the cream was optimized. Finally, the best prescription was obtained: 6g of liquid paraffin, 7.5g of octadecyl alcohol, 10g of white vaseline, 2g of magnolia: lavender (2:1) volatile oil, 0.1g of ethyl paraben, 1g of sodium dodecyl sulfate, 5g of glycerol, and water was added to 100g. That is, the magnolia lavender volatile oil cream preparation was obtained.

[0113] Example 3 Preparation of the Medicinal Suppository of the Present Invention

[0114] 1) Weigh 5.0 g of polyethylene glycol 6000, 3.0 g of polyethylene glycol 4000 and an appropriate amount of distilled water, place them in a weighed evaporating dish, heat in a water bath to melt, and stir evenly to prepare 10.0 g of a water-soluble matrix.

[0115] 2) Accurately weigh 0.15 g of volatile oil of magnolia: lavender (2:1), place it in a weighed evaporating dish, add 0.015 g of polysorbate-80 and an appropriate amount of potassium sorbate, and then add 1.35 g of the prepared molten polyethylene glycol mixed matrix, heat to melt in a 60-65°C water bath, stir evenly, and quickly pour into a suppository mold that has been coated with a lubricant, solidify and demould, and use absorbent paper to absorb the moisture on the surface of the suppository to obtain a suppository.

[0116] Example 4 Preparation of the Injectable Emulsion of the Present Invention

[0117] Preparation method:

[0118] 1) Weigh 100 g of volatile oil of magnolia and lavender (2:1) and 100 g of caprylic and capric triglyceride for injection, mix them, heat them in a water bath to 78° C., add 12 g of egg yolk lecithin for injection, shear to dissolve, and stir evenly to obtain an oil phase;

[0119] 2) Take 750 ml of water for injection, add 22.5 g of glycerol, stir to dissolve, and heat to 78°C to obtain the aqueous phase;

[0120] 3) The oil phase and the aqueous phase are mixed at a temperature of 78°C, and emulsified for 8 minutes using a shear emulsifier (speed of 20,000 rpm) to obtain colostrum; the colostrum is further emulsified using a high-pressure homogenizer (pressure of 15,000 psi), the injection water is quantitatively adjusted to 1,000 ml, the pH value is adjusted to 8.50 using a sodium hydroxide solution, filtered using a microporous filter membrane, packaged in plastic or glass bottles, filled with nitrogen, sealed, and sterilized in a rotary high-pressure steam autoclave at 121°C for 15 minutes to obtain an injectable emulsion.

[0121] Example 4 Quality testing method of the drug of the present invention

[0122] 1 Identification of essential oil components of magnolia and lavender

[0123] 1.1 Preparation of essential oil samples of Magnolia officinalis and Lavender

[0124] Accurately measure 100 μL of magnolia volatile oil and 100 μL of lavender volatile oil into two different 10 mL brown volumetric flasks, make up to volume with n-hexane, mix well, add anhydrous sodium sulfate to remove moisture, filter through a 0.22 μm filter membrane, and drop into a sample injection bottle for later use.

[0125] 1.2 GC-MS experimental conditions

[0126] The mass spectrometry conditions of volatile oil of Magnolia odorifera were as follows: Agilent HP-5ms (30m×250μm×0.25μm) capillary column, carrier gas He, no splitting, injection volume 3.0μL, flow rate 1mL / min. The starting temperature was 55℃, 8℃ / min to 80℃, 6℃ / min to 160℃ (holding time 2min), 8℃ / min to 200℃, 3℃ / min to 250℃ (holding time 2min). The mass spectrometry conditions were as follows: ionization source EI ion source temperature 230℃, ionization energy 70eV, transfer line temperature 280℃, ion source temperature 230℃, quadrupole temperature 150℃, solvent delay time 3min, scanning mass scanning range 28–555amu.

[0127] Lavender essential oil mass spectrometry conditions: Agilent HP-5ms (30m×250μm×0.25μm) capillary column, carrier gas He, no splitting, injection volume 1.0μL, flow rate 1mL / min. The starting temperature was 40℃ (holding time 1min), 5℃ / min increased to 90℃ (holding time 1min), 10℃ / min increased to 260℃ (holding time 6min). The mass spectrometry conditions are as follows: ionization source EI ion source temperature 230℃, ionization energy 70eV, transfer line temperature 280℃, ion source temperature 230℃, quadrupole temperature 150℃, solvent delay time 5min, scanning mass scanning range 30–400amu.

[0128] 1.3 Data processing

[0129] The data used were processed by data analysis software to screen the content of essential oils of magnolia and lavender. The components were screened based on the matching degree and relevant literature using the NIST standard library search.

[0130] 1.4 Data Analysis Results

[0131] The analysis and identification showed that the essential oil of magnolia bud contained 21 active ingredients, and the results are shown in Table 10. The analysis and identification showed that the essential oil of lavender bud contained 14 active ingredients, and the results are shown in Table 11.

[0132] Table 10 Analysis of components of volatile oil from Magnolia odorifera

[0133]

[0134]

[0135] Table 11 Analysis of lavender volatile oil components

[0136]

[0137]

[0138] The beneficial effects of the present invention are demonstrated by pharmacodynamic tests as follows.

[0139] Experimental Example 1 Effect of magnolia and lavender combined with volatile oil cream preparation on chronic prostatitis 1 Experimental method

[0140] 1.1 Experimental animals

[0141] 100 male Sprague-Dawley SPF rats (180-220 g), certificate number: SCXK (Shaanxi) 2018-001, were purchased from the Experimental Animal Center of the School of Medicine of Xi'an Jiaotong University and were kept in the animal room of the Chinese Medicine Pharmacology Laboratory of Shaanxi University of Chinese Medicine (room temperature 23-26 ° C, relative humidity 60%-24%). During the adaptive feeding period, the rats were free to eat and drink water, which lasted for one week.

[0142] 1.2 Establishment and sampling of rat chronic prostatitis model

[0143] Carrageenan is a chemical agent extracted from plants and is widely used to induce rat chronic prostatitis animal model. Its main function is to increase the synthesis of local prostaglandins and interact with vasoactive peptides and kinins, thereby inducing edema and establishing chronic prostatitis. 100 rats were randomly divided into a blank group, a model group, a celecoxib group, a magnolia volatile oil group, a lavender volatile oil group, a magnolia: lavender (1:1) volatile oil compatibility group, a magnolia: lavender (2:1) volatile oil compatibility group, a magnolia: lavender (3:1) volatile oil compatibility group, a magnolia: lavender (1:2) volatile oil compatibility group, and a lavender (2:1) volatile oil compatibility cream group, with 10 rats in each group, and the experiment was carried out (wherein the ratios are the mass ratios of magnolia volatile oil to lavender volatile oil). A stable rat chronic prostatitis model with relatively consistent individual responses was prepared by injecting 100 μL of 3% w / v carrageenan into the left and right ventral lobes of the prostate. The rats were sutured after successful injection. All rats were injected with 0.2 mL of sodium penicillin for three consecutive days. One week after the modeling, the rats with chronic prostatitis were treated. The celecoxib group was gavaged with celecoxib capsules (18 mg kg -1 ); All drug groups, including the volatile oil group and the cream group, had the same dosage, i.e., 50 mg kg -1 After treatment, 2% sodium pentobarbital (40 mg kg -1 ) were injected for anesthesia, and whole blood was collected from all rats. After static centrifugation, serum was aliquoted and stored at -20°C for future use; all rats were euthanized, and prostate tissue was taken, washed with physiological saline, and weighed for the determination of prostate index. Part of the prostate tissue was fixed with 4% paraformaldehyde and stored at room temperature; part was quickly frozen with liquid nitrogen and transferred to a -80°C refrigerator for subsequent tissue protein detection.

[0144] 1.3 Detection of TNF-α, IL-6, and IL-1β in rat serum

[0145] The ELISA scientific research kit was used to detect the levels of TNF-α, IL-6 and IL-1β in the serum of each group of rats according to the method in the kit instructions. Then, an ELISA reader was used to detect the levels of inflammatory factors in the serum of each group and a standard curve was drawn.

[0146] 1.4 HE staining to observe the morphological changes of rat prostate tissue cells

[0147] Prostate tissues fixed in 4% paraformaldehyde and embedded in paraffin were obtained, the tissues were cut into 5 μm thick sections and stained with hematoxylin-eosin (HE), and pathological examination was performed under a microscope at 200 times magnification.

[0148] 1.5 Immunohistochemistry

[0149] After the prostate tissue is sliced, it is soaked twice and then hydrated with an ethanol gradient (100%, 95%, 85%, 75%) and double distilled water. The sections are then placed in 0.01M sodium citrate buffer for high-pressure antigen retrieval for 20-30 minutes, 3% H2O2 is added to block endogenous peroxidase, and then incubated in a humidified chamber for 10 minutes. Next, non-immune, normal goat serum is added to block nonspecific antigens, and then incubated in a 37°C humidified chamber for 30 minutes. Subsequently, the primary antibody is added and placed in a 4°C incubation overnight. Next, the sample is removed and washed three times for 3 minutes at room temperature. Subsequently, a secondary antibody labeled with HRP is added and incubated at 37 degrees Celsius for 60 minutes. Finally, DAB staining is used, followed by rinsing with tap water and counterstaining with hematoxylin. Then, 0.1% hydrochloric acid alcohol is used for differentiation, and the degree of staining is observed under a microscope. Finally, dehydration, transparency, and sealing operations are performed.

[0150] 1.6 Statistical methods

[0151] The data were analyzed using GraphPad Prism 9.0.1 software, and the independent sample t test was used for comparison between the two groups. The mean ± standard deviation was used. The data are shown in Table 1 , and p < 0.05 indicates statistical significance.

[0152] 2 Results and analysis

[0153] 2.1 Comparison of prostate index among rats in each group

[0154] The effect of the drug administration group on chronic prostatitis in rats was preliminarily evaluated by prostate index. Figure 3As shown in A. The bar graph shows that compared with the blank group, the prostate index of the model group was significantly increased (p<0.01). Compared with the model group, the prostate index of the celecoxib capsule group, magnolia volatile oil group, lavender volatile oil group, magnolia: lavender (1:1) volatile oil compatibility group, magnolia: lavender (2:1) volatile oil compatibility group, magnolia: lavender (3:1) volatile oil compatibility group, magnolia: lavender (1:2) volatile oil compatibility group were all reduced, and there were differences (p<0.01).

[0155] The prostate index of the magnolia:lavender (2:1) essential oil combination group was lower than that of other drug groups (p<0.05 and p<0.01).

[0156] Depend on Figure 4 As shown in A, the prostate index of the magnolia: lavender (2:1) volatile oil combination cream group was lower than that of the magnolia: lavender (2:1) volatile oil combination group, and there was a difference (p<0.05).

[0157] 2.2 Levels of TNF-α, IL-6, and IL-1β in rat serum

[0158] Figure 3 (BD) The results showed that compared with the blank group, the serum inflammatory factors TNF-α, IL-6 and IL-1β in the model group increased significantly, and there were significant differences (p<0.01). Compared with the model group, the serum TNF-α, IL-6 and IL-1β levels in the celecoxib capsule group, magnolia volatile oil group, lavender volatile oil group, magnolia: lavender (1:1) volatile oil compatibility group, magnolia: lavender (2:1) volatile oil compatibility group, magnolia: lavender (3:1) volatile oil compatibility group, magnolia: lavender (1:2) volatile oil compatibility group were decreased (p<0.05 and p<0.01).

[0159] The levels of TNF-α, IL-6, and IL-1β in serum of the magnolia:lavender (2:1) volatile oil combination group were lower than those of other drug-administered groups (p<0.05 and p<0.01).

[0160] Depend on Figure 4 As shown in (BD), compared with the magnolia: lavender (2:1) volatile oil compatibility cream group, the serum TNF-α, IL-6, and IL-1β levels in the magnolia: lavender (2:1) volatile oil compatibility group were lower (p<0.05 and p<0.01).

[0161] The prostate index and kit data are shown in Tables 12, 13 and 14.

[0162] Table 12 Prostate Index and Kit Data Table

[0163]

[0164] Note: Compared with the blank group, ## p<0.01; compared with the model group, * p<0.05, ** p<0.01

[0165] Table 132:1 Comparison of prostate index and kit data between the combination group and other drug administration groups

[0166]

[0167] Note: Compared with the combination of magnolia and lavender (2:1), * p<0.05, ** p<0.01

[0168] Table 14 Prostate index and kit data of cream and volatile oil groups

[0169]

[0170] Note: Compared with the combination of magnolia and lavender (2:1), * p<0.05, ** p<0.01

[0171] 2.3 HE staining results

[0172] The results of HE staining are as follows Figure 5 The blank group had normal prostate tissue structure, full acinar colloid, and no obvious loss; the model group had abnormal structure, with a large number of inflammatory cells infiltrating the interstitial tissue, and the inflammatory cells invaded the epithelial cells, causing necrosis of some epithelial cells; the magnolia volatile oil group and the lavender volatile oil group showed slight improvement; the celecoxib capsule group, magnolia: lavender (1:1) volatile oil compatibility group, magnolia: lavender (2:1) volatile oil compatibility group, magnolia: lavender (3:1) volatile oil compatibility group, and magnolia: lavender (1:2) volatile oil compatibility group all showed different degrees of improvement.

[0173] Figure 6 The results showed that the magnolia: lavender (2:1) volatile oil combined cream group was improved compared with the magnolia: lavender (2:1) volatile oil combined cream group. Among them, the overall structure of the prostate tissue in the magnolia: lavender (2:1) volatile oil combined cream group was basically normal, and no obvious inflammatory cell infiltration was observed.

[0174] 2.4 Immunohistochemistry results

[0175] Immunohistochemistry was used to measure the expression levels of COX2, p-AKT, p-p65, and p-PI3K in rat prostate tissue. Figure 7 and Figure 8 The results showed that compared with the blank group, the expression levels of COX2, p-AKT, p-p65 and p-PI3K in the model group were significantly increased (p<0.05). Compared with the model group, the expression levels of COX2, p-AKT, p-p65 and p-PI3K in the celecoxib capsule group, magnolia volatile oil group, lavender volatile oil group, magnolia: lavender (1:1) volatile oil compatibility group, magnolia: lavender (2:1) volatile oil compatibility group, magnolia: lavender (3:1) volatile oil compatibility group, magnolia: lavender (1:2) volatile oil compatibility group were all decreased to varying degrees compared with the model group (p<0.05 and p<0.01).

[0176] The expression levels of COX2, p-AKT, p-p65 and p-PI3K in the prostate of the magnolia:lavender (2:1) essential oil combination group were lower than those of the other drug-treated groups (p<0.05 and p<0.01).

[0177] Fig. 9 and Fig.10 The results showed that the magnolia: lavender (2:1) volatile oil combined cream group had a decrease in COX2, p-AKT, p-p65 and p-PI3K in the prostate tissue compared with the magnolia: lavender (2:1) volatile oil combined group (p<0.05 and p<0.01). This shows that the magnolia: lavender (2:1) volatile oil combined cream can better reduce the expression of COX2, p-AKT, p-p65 and p-PI3K in the prostate tissue of rats with chronic prostatitis.

[0178] The immunohistochemical data are shown in Tables 15, 16 and 17.

[0179] Table 15 Immunohistochemistry results data table

[0180]

[0181]

[0182] Note: Compared with the blank group, ## p<0.01; compared with the model group, * p<0.05, ** p<0.01

[0183] Table 16 Comparison of immunohistochemical data between the 2:1 combination group and other drug administration groups

[0184]

[0185] Note: Compared with the combination of magnolia and lavender (2:1), * p<0.05, ** p<0.01

[0186] Table 17 Cream immunohistochemistry results data table

[0187]

[0188] Note: Compared with the combination of magnolia and lavender (2:1), * p<0.05, ** p<0.01

[0189] 3 Summary and discussion

[0190] The rat chronic prostatitis model was established by using 3% w / v carrageenan. The study found that compared with the model group, the prostate index of the lavender volatile oil, magnolia volatile oil, magnolia: lavender (1:1) volatile oil compatibility group, magnolia: lavender (2:1) volatile oil compatibility group, magnolia: lavender (3:1) volatile oil compatibility group, magnolia: lavender (1:2) volatile oil compatibility group, magnolia: lavender (2:1) volatile oil compatibility cream group were all smaller, and the secretion of inflammatory factors TNF-α, IL-1β, and IL-6 in rat serum was also reduced. At the same time, the results of HE staining showed that the infiltration of inflammatory cells in the prostate tissue of the rats in the drug-treated group was reduced, and the number of mast cells was reduced. Immunohistochemistry was used to test the key proteins COX2, p-AKT, p-p65 and p-PI3K in rat prostate tissue. The results showed that the drug administration group could reduce the expression of COX2, p-AKT, p-p65 and p-PI3K in the prostate tissue of rats with chronic prostatitis. The experimental results showed that the magnolia: lavender (2:1) volatile oil cream group had the best results and achieved the therapeutic effect, confirming the efficacy of the magnolia lavender volatile oil cream group.

Claims

1. Use of magnolia volatile oil in preparing medicine for chronic prostatitis.

2. The use according to claim 1, characterized in that: The medicine is administered rectally or injected locally directly into the prostate.

3. A pharmaceutical composition for treating chronic prostatitis, characterized in that: It contains magnolia volatile oil and lavender volatile oil; the weight ratio is: magnolia volatile oil 1.5-2.5 parts, lavender volatile oil 0.5-1.5 parts; The magnolia volatile oil contains 1%-60% w / w eucalyptol and 1%-30% w / w farnesol; the lavender volatile oil contains 5%-55% w / w linalool and 3%-40% w / w linalyl acetate.

4. The pharmaceutical composition for treating chronic prostatitis according to claim 3, characterized in that: The weight ratio of magnolia volatile oil and lavender volatile oil is: 2 parts of magnolia volatile oil and 1 part of lavender volatile oil.

5. The pharmaceutical composition for treating chronic prostatitis according to claim 3 or 4, characterized in that: The raw material is used as an active ingredient, and pharmaceutically acceptable auxiliary materials or auxiliary ingredients are added to prepare a commonly used pharmaceutical preparation; the preparation is a rectal administration and direct local injection into the prostate.

6. The pharmaceutical composition for treating chronic prostatitis according to claim 5, characterized in that: The rectal administration preparations include suppositories, enemas, foams, gels and creams.

7. The pharmaceutical composition for treating chronic prostatitis according to claim 6, characterized in that: The cream is an O / W cream, wherein each 100 g contains the following raw materials and matrix by weight: Liquid paraffin 6g, octadecyl alcohol 7.5g, white vaseline 10g, magnolia: lavender essential oil (2:1) 2g, ethyl paraben 0.1g, sodium lauryl sulfate 1g, glycerin 5g.

8. A method for preparing the pharmaceutical composition for treating chronic prostatitis according to claim 7, characterized in that: The emulsion comprises the following steps: a. Weigh the raw materials of each weight ratio; The oil phase is liquid paraffin and white vaseline, and the water phase is stearyl alcohol, glycerin and water; b. Heat the oil phase and water phase to 80°C respectively, and add volatile oil after the oil phase is completely melted; c. Continuously stir the oil phase and the water phase to mix them well; add ethyl paraben and sodium lauryl sulfate to the water phase; d. When the temperatures of the two phases are the same, slowly pour the water phase into the oil phase and continue stirring in the same direction; first increase the speed, then gradually slow down until emulsification is complete; after stopping heating, continue stirring to room temperature until the cream is formed.

9. Use of the pharmaceutical composition according to any one of claims 3 to 7 in the preparation of a medicament for chronic prostatitis.

10. A method for detecting the pharmaceutical composition for treating chronic prostatitis according to any one of claims 3 to 7, characterized in that: It adopts GC-MS method to detect, which includes the following steps: a. Sample pretreatment: Accurately measure 100 μL of magnolia volatile oil and 100 μL of lavender volatile oil into two different 10 mL brown volumetric flasks, dilute to volume with n-hexane, mix well, add anhydrous sodium sulfate to remove moisture, filter through a 0.22 μm filter membrane, and drop into a sample injection bottle for later use; b. GC-MS conditions are: The gas chromatography-mass spectrometry conditions of volatile oil of Magnolia odorifera were as follows: Agilent HP-5ms (30m×250μm×0.25μm) capillary column, carrier gas He, no splitting, injection volume 3.0μL, flow rate 1mL / min; the starting temperature was 55℃, 8℃ / min increased to 80℃, 6℃ / min increased to 160℃ (holding time 2min), 8℃ / min increased to 200℃, 3℃ / min increased to 250℃ (holding time 2min); the mass spectrometry conditions were as follows: ionization source EI ion source temperature 230℃, ionization energy 70eV, transfer line temperature 280℃, ion source temperature 230℃, quadrupole temperature 150℃, solvent delay time 3min, scanning mass scanning range 28–555amu; Mass spectrometry conditions for lavender essential oil: Agilent HP-5ms (30m×250μm×0.25μm) capillary column, carrier gas He, no splitting, injection volume 1.0μL, flow rate 1mL / min; starting temperature 40℃ (holding time 1min), 5℃ / min to 90℃ (holding time 1min), 10℃ / min to 260℃ (holding time 6min); mass spectrometry conditions are as follows: ionization source EI ion source temperature 230℃, ionization energy 70eV, transfer line temperature 280℃, ion source temperature 230℃, quadrupole temperature 150℃, solvent delay time 5min, scanning mass scanning range 30–400amu.

Citation Information

Patent Citations

  • Application of lavender volatile oil in preparation of medicine for treating chronic prostatitis, lavender volatile oil cream and application of lavender volatile oil cream

    CN118717830A